Tri Valley Plastic Surgery makes a clear offer: semaglutide and tirzepatide treatment within a Bay Area plastic surgery and Med Spa practice. The harder question is what evidence supports the particular service a patient would receive. A published medication name, monthly price and consultation process establish that a program is advertised. They do not establish which product is dispensed, whether a particular preparation has FDA approval, or what results this clinic’s patients achieve.
This review separates those questions using public documentation consulted October 19, 2026. Tri Valley describes clinician assessment, monthly monitoring, virtual consultations and local medication pickup, giving prospective patients several concrete details to investigate. Important gaps remain around product identity, included fees, pharmacy arrangements and cancellation. The appropriate reading is neither that missing details prove poor care nor that a familiar ingredient name supplies all the missing evidence. The distinction between provider documentation and clinical evidence is central to evaluating this program.
At a glance
- Documented offering
- Tri Valley Plastic Surgery explicitly advertises semaglutide and tirzepatide at its Dublin, California, practice.
- Semaglutide pricing
- The semaglutide page lists a $50 initial consultation, medication at $500 for the first month and $600 for each subsequent month.Sources: [8]
- Tirzepatide pricing
- Tirzepatide is advertised at $700 for the first month and $800 for each subsequent month; the page does not establish whether the $50 consultation fee also applies.
- Assessment and monitoring
- The semaglutide process begins with a physician assistant and describes monthly follow-ups. Tirzepatide check-ins include weight, blood sugar and other relevant indicators.
Start with the product, not the ingredient name
The most consequential documentation gap is also the simplest: what exactly would be prescribed and dispensed? Tri Valley expressly offers semaglutide and tirzepatide, but the consulted descriptions do not name a brand, manufacturer, dispensing pharmacy or presentation. They also do not establish whether the preparations are compounded. Those omissions prevent a reader from connecting the advertised service to a specific product’s approval status and supporting evidence. They are reasons to request clarification, not grounds to assume a particular pharmacy arrangement.
The tirzepatide page uses FDA-approval language without identifying the product patients receive. FDA approval attaches to a particular product, not to a clinic or to every preparation containing a named ingredient. FDA says compounded preparations are not approved and do not receive its premarket review for safety, effectiveness and quality. Nonapproval alone, however, does not demonstrate clinical inequivalence or establish that a provider’s care is good or bad.
FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. That context matters only conditionally here: the documentation does not establish compounding at Tri Valley. Before interpreting the practice’s claims, ask for the actual prescription product and pharmacy. Our explanation of approved medicines and compounded preparations separates those evidence questions without treating either an ingredient name or missing information as a verdict.
What the practice and its clinical team actually document
Tri Valley is a plastic surgery practice with a Med Spa, rather than a publicly documented nationwide medication-only platform. It identifies Dublin, California, as its location and says it serves the Bay Area and patients around the world. That broad description of the practice should not be read as confirmation that its GLP-1 program can prescribe everywhere. The semaglutide page offers virtual and in-person consultations, but the consulted documentation does not list states where remote treatment is available.
The website presents Steven Williams as a board-certified plastic and reconstructive surgeon and a diplomate of the American Board of Plastic Surgery. It says he oversees the semaglutide program. The practice also introduces Philip Wasicek as a double board-certified plastic surgeon focused on facial aesthetic surgery. These are provider-published credential statements, not independently verified findings in this review; Wasicek’s introduction does not establish that he personally manages weight-treatment patients.
For semaglutide, the stated starting point is a meeting with a PA, or physician assistant, to discuss weight goals and medical history. The program promises a comprehensive health assessment and individualized planning. That identifies a clinical entry point, but not the full assessment protocol: required tests, complete eligibility criteria and the clinician responsible for each later decision are not laid out. Prospective patients should distinguish program supervision from the person who actually evaluates, prescribes and follows their care.
Assessment, medication access and monthly follow-up
The semaglutide page says a patient may leave the consultation with medication if the assessment is favorable. This is conditional access, not a guaranteed prescription or guaranteed same-day supply. The starting page also says patients receive shots at monthly appointments and advertises extended-hours medication pickup. These statements establish that local access is part of the offering, but do not resolve who administers each injection, what quantity is dispensed or what instructions accompany medication taken home.
Monthly appointments should not be converted into a dosing schedule. The documentation does not specify the anatomical injection route, home-use supplies or a complete administration process. Nor does it describe home shipping, refrigeration arrangements or delivery timing. For someone expecting a remote, shipped-to-door program, these are substantial operational questions rather than minor details. Virtual consultation availability by itself does not establish mail-order medication fulfillment.
Follow-up is more clearly described. Semaglutide patients are told to expect monthly visits to track progress. Tirzepatide patients return for monthly check-ins covering weight, blood sugar and other relevant health indicators, following an assessment of health history, goals and lifestyle. That is a documented monitoring plan, not published evidence that monitoring consistently occurs or produces particular outcomes. Ask who reviews symptoms between visits and how to reach that person; program-specific response times and urgent support arrangements are not stated.
Published prices are useful, but do not define the complete bill
Tri Valley publishes concrete medication prices rather than requiring every prospective patient to request a quote. Semaglutide is $500 for the first month and $600 for each subsequent month, with a separately stated $50 initial consultation. Tirzepatide is $700 for the first month and $800 thereafter. These are monthly descriptions, not explicitly four-week billing periods. The pages do not identify the formulation, presentation or dispensed quantity associated with those charges, limiting product-level price comparison.
Both medications have advertised four- and seven-month package options. Their prices, payment timing and commitment terms are not disclosed in the consulted passages; package duration alone establishes neither supply quantity nor a minimum contractual obligation. Semaglutide financing details and a payment calculator are available on request, while tirzepatide financing is discussed during consultation. No published information here resolves interest, approval requirements or whether financing changes cancellation obligations.
The monthly prices also do not clearly establish whether follow-ups, laboratory work or supplies are included. Insurance coverage and insurer billing for these programs remain unconfirmed. Specific renewal, cancellation, pause and refund terms are absent from the consulted documentation. The website terms, last updated January 1, 2026, describe general informational materials and website use; ending website access is not a treatment cancellation policy. Obtain a written service agreement rather than treating those general terms as the medication contract.
| Item | Documented price or option | Unresolved detail |
|---|---|---|
| Semaglutide consultation | $50 initial consultation | Whether the same fee applies to tirzepatide |
| Semaglutide medication | $500 first month; $600 each subsequent month | Product, quantity and included ancillary services |
| Tirzepatide medication | $700 first month; $800 each subsequent month | Product, quantity and included ancillary services |
| Treatment packages | Four- and seven-month options for both medications | Package prices, payment timing and commitment terms |
| Financing | Available; details on request or during consultation | Interest, eligibility and repayment conditions |
Trial evidence is not a clinic performance report
There is clinical research on these medicines, but that research does not supply Tri Valley’s missing outcome data. STEP 1 studied 1,961 adults with obesity, or overweight plus a weight-related condition, without diabetes over 68 weeks. Both groups received lifestyle intervention. Mean weight change was minus 14.9% with studied subcutaneous semaglutide 2.4 mg weekly and minus 2.4% with placebo. Those details identify a research regimen and population, not instructions for a reader or a forecast for this practice.
In STEP 1, gastrointestinal events led to discontinuation in 4.5% of the semaglutide group and 0.8% of the placebo group; Novo Nordisk funded the study. SURMOUNT-1 separately studied tirzepatide in adults without diabetes over 72 weeks and was funded by Eli Lilly, with gastrointestinal adverse events most common. It was not a trial of Tri Valley. Our guide to reading SURMOUNT-1 without ranking providers explains why published drug research cannot establish a clinic’s effectiveness.
Tri Valley’s pages also promote broader cardiovascular benefits and, for semaglutide, possible reduction in certain cancer risks. These are provider marketing claims; the consulted documentation does not demonstrate such outcomes in its patients or justify extending them to every product or indication. Testimonials about surgery, fillers or Botox are likewise not weight-program outcome evidence. A useful provider-level report would need identifiable treatment products, a defined patient population, follow-up duration and transparent outcome reporting—not simply favorable accounts of other services.
Safety information needs more than a short side-effect description
The tirzepatide page highlights mild nausea or digestive discomfort and describes monitoring. That wording should not be treated as a complete safety discussion or evidence that adverse effects will be mild for a particular patient. The consulted program materials do not provide comprehensive contraindications, required testing or full eligibility rules. Both medication pages discuss use in people without diabetes, but that does not make everyone without diabetes eligible or establish which product would be appropriate.
NIDDK advises discussing benefits, side effects, other medicines, health conditions, family history and costs with a clinician. It also identifies supplements, allergies and pregnancy plans as relevant discussion topics. Tri Valley’s tirzepatide program encourages regular activity and balanced nutrition, but does not describe an included nutrition service. Readers should ask what support actually accompanies medication rather than interpreting general lifestyle advice as access to a dietitian, coaching sessions or a structured behavioral program.
If medication is supplied for home use, clear instructions and an identifiable pharmacy become especially important. FDA has received reports of compounded-medication measurement or administration errors, some involving hospitalization; those reports are not a Tri Valley event rate. FDA also explicitly advises not using an injectable GLP-1 product that arrives warm or inadequately refrigerated and contacting the provider or pharmacy. Tri Valley does not document shipping here, so this is conditional safety context, not a claim about its deliveries.
Surgery credits and referrals are commercial terms, not outcome evidence
Tri Valley connects weight treatment with its aesthetic services. It advertises skin tightening and body contouring after weight loss, with customized quotes following a private physical assessment and medical review. These services are not established as included in medication pricing. The post-weight-loss page also describes candidates with maintained weight loss, excess skin, good health, no uncontrolled medical problems and nonsmoking status. Those are criteria for the additional procedures, not published GLP-1 enrollment requirements.
A semaglutide promotion offers a credit equal to 50% of program expenses toward surgery after reaching a target weight. The surgery must have a minimum surgeon fee of $5,000, and the maximum applicable credit is $3,600. This is a conditional surgical credit, not a cash refund or evidence of medication effectiveness. The consulted promotion does not provide an expiration date, so a patient considering it should obtain current written terms before assigning it financial value.
The referral promotion offers $200 in credit when a referred patient enrolls in semaglutide. It can be combined with other promotions and accumulated through multiple referrals, but excludes skincare and neurotoxin banks. Separately, the Med Spa’s $100 new-patient offer excludes weight-loss treatments and neurotoxin banks even though it can combine with other promotions. These distinctions matter: a broadly advertised aesthetic discount should not be subtracted from a GLP-1 bill unless its specific terms permit that use.
Use the consultation to close specific documentation gaps
The booking instructions say to mention a preference for a virtual consultation in the notes. If available appointments do not work, the program page gives (925) 875-9011. The main practice is listed at 11820 Dublin Boulevard, Dublin, CA 94568, open Monday through Friday, 8 a.m. to 5 p.m. The Med Spa is at 11828 Dublin Boulevard, with later Thursday and Friday hours and Saturday availability. Confirm which location and pickup hours apply to the weight program.
A productive consultation should produce more than reassurance about a familiar medication name. Request the exact product, presentation, pharmacy, administration arrangements, included monitoring and written billing terms. Ask which clinician handles symptoms between monthly appointments and whether virtual care is available where you live. The GLP-1 medical-claims checklist can help organize that conversation. Answers should connect the actual treatment being offered to its evidence rather than relying on unrelated testimonials or the practice’s general reputation.
Questions & answers
Does Tri Valley dispense Ozempic or another named brand?
The consulted documentation does not establish a dispensed brand. Its references to “Ozempic face” do not confirm that Ozempic is prescribed or supplied. The documented offerings are semaglutide and tirzepatide by ingredient name. Ask for the exact product, manufacturer, presentation and pharmacy before interpreting approval claims or comparing prices with another program.
Can I complete the program entirely online?
Virtual consultations are advertised, and the booking instructions ask patients to state that preference in the notes. That does not establish fully remote treatment, nationwide prescribing or home delivery. The practice also describes local appointments and medication pickup. Confirm geographic eligibility and how medication would reach you before assuming an online consultation removes the need to visit Dublin.
Are monthly check-ins included in the medication price?
The pages describe monthly follow-up but do not clearly state that the advertised medication charges include those visits, laboratory testing or supplies. Semaglutide has a separately listed $50 initial consultation. Ask for an itemized explanation of the first payment and subsequent payments, including any separate visit or testing charges, rather than assuming the monthly figure is all-inclusive.
Do four- or seven-month packages require advance payment?
The consulted descriptions do not say. Both medication pages advertise those package lengths, but do not publish package amounts, advance-payment requirements or minimum commitments. Financing availability does not resolve those questions. Obtain the package agreement and financing terms separately, including what happens if treatment changes or stops; a package duration is not itself a refund or cancellation policy.
Can someone without diabetes request an assessment?
Both program pages discuss treatment for people without diabetes. They also describe clinical assessment, so those statements should not be read as guaranteed eligibility or a guaranteed prescription. The public documentation does not provide complete age, medical-history, testing or other enrollment criteria. Ask the treating clinician which product-specific and practice-specific requirements apply to the assessment.
Does the semaglutide surgery promotion reduce my medication bill?
The documented promotion is a credit toward qualifying future surgery after reaching a target weight, not a stated reduction in monthly medication charges. It offers 50% of program expenses, subject to a $3,600 maximum credit and a minimum surgeon fee of $5,000. Confirm current eligibility, eligible expenses and timing in writing; the consulted promotion does not provide an expiration date.
Our assessment
Tri Valley documents a genuine advertised GLP-1 offering with specific monthly medication prices, clinician assessment, local access and planned follow-up. Those details make the service more concrete than an ingredient-only advertisement. Its public evidence is nevertheless incomplete where product identity, dispensing responsibility, total charges and treatment-contract terms matter most. Published clinical trials do not fill those gaps or establish this practice’s outcomes. A reasonable next step for an interested patient is a documentation-focused consultation: obtain the exact product and pharmacy, an itemized bill and written ongoing-care terms before deciding whether the program fits their needs.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Wilding et al. (2021): STEP 1 semaglutide trial ↗
- Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
- Tri Valley Plastic Surgery — get started with weight loss ↗
- Tri Valley Plastic Surgery — weight loss shots/post weight loss ↗
- Tri Valley Plastic Surgery — about/about tri valley plastic surgery ↗
- Tri Valley Plastic Surgery — weight loss shots/semaglutide ↗
- Tri Valley Plastic Surgery — weight loss shots/tirzepatide ↗
- Tri Valley Plastic Surgery — weight loss shots/ozempic face ↗
- Tri Valley Plastic Surgery — official website ↗
- Tri Valley Plastic Surgery — terms and conditions ↗